Evaluation of diagnostic test for the superficial bladder cancer based intravesical instillation of pirarubicin (THP) prior to transurethral resection (TUR)

Evaluation of diagnostic test for the superficial bladder cancer based intravesical instillation of pirarubicin (THP) prior to transurethral resection (TUR) - The significance of intravesical instillation of pirarubicin (THP) for preoperative superficial bladder cancer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018932

Enrollment

Registered

2015-09-07

Start date

2015-09-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Superficial bladder cancer

Interventions

We inject THP30mg to the urinary bladder for every other week to achieve 8 times as adjuvant therapy. After injections, we observe the bladder cancer recurrence rate between THP taken lesions and THP

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: superficial cancer

Exclusion criteria

Exclusion criteria: progressive cancer

Design outcomes

Primary

Measure	Time frame
We study to confirm a tendency whether superficial bladder cancer has take THP, and present whether this finding useful for determining a cancerous lesion. For preparation, we inject THP15mg and distilled water 15ml to urinary bladder 30 minitues before for operation. We also perform comperative examination among THP taken lesions, lesions by white light and lesions by NBI histopathologically.	—

Secondary

Measure	Time frame
To evaluate the recurrence rate between THP taken lesions and its untaken lesions at 6, 12 months later from last THP injection date for adjuvant therapy	—

Countries

Japan

Contacts

Public ContactHironori Betsunoh

Dokkyo Medical University Urology

hirobets@dokkyomed.ac.jp0282872162

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026